| Literature DB >> 31233832 |
Erica M Weidler1, Maria E Linnaus2, Arlene B Baratz3, Luis F Goncalves4, Smita Bailey4, S Janett Hernandez5, Veronica Gomez-Lobo6, Kathleen van Leeuwen5.
Abstract
Historically, individuals with androgen insensitivity syndrome (AIS) were managed with removal of gonadal tissue at various ages to avert the risk of gonadal malignancy. Recently, clinical practice changed, with gonadectomy being postponed until late adolescence. Adolescents and adults with complete AIS have questioned this approach. Additionally, testicular germ cell tumors are increasingly believed to be quite rare with rates as low as 0% in molecularly confirmed individuals with AIS. Gonadectomy deprives patients of the benefits of their endogenous hormones and potential fertility. Furthermore, human rights organizations advocate for deferring irreversible surgery in conditions known as differences of sex development, which includes AIS, to allow patient autonomy in decision-making. Recent literature supports an approach that uses risk stratification to manage gonads in AIS. Herein we review what is known about malignancy risk in the different subtypes of AIS and propose a management protocol for gonad retention.Entities:
Keywords: Androgen insensitivity syndrome; Gonadectomy; Gonads; Malignancy risk
Mesh:
Year: 2019 PMID: 31233832 PMCID: PMC6917890 DOI: 10.1016/j.jpag.2019.06.005
Source DB: PubMed Journal: J Pediatr Adolesc Gynecol ISSN: 1083-3188 Impact factor: 1.814